ImageneBio, Inc. SEC Filings

ImageneBio, Inc. reported that Chief Executive Officer Kristin Yarema received new equity awards as part of her compensation. She was granted an option to buy 128,100 shares of common stock at an exercise price of $6.20 per share, vesting over four years starting March 15, 2027. She also received 85,400 restricted stock units, each convertible into one share of common stock, with 25% vesting on March 15, 2027 and the rest in equal quarterly installments over the following three years, subject to continued service.

ImageneBio, Inc. announced that it has agreed to a mutual separation with Erin Butler, its Senior Vice President, Finance & Administration and Principal Accounting Officer, effective March 20, 2026. After that date, she will no longer serve as the company’s Principal Accounting Officer and is expected to receive severance benefits under her existing Severance Rights Agreement.

The board of directors has appointed Bob Lally, age 63, currently Senior Vice President, Finance & Operations, to serve as Principal Accounting Officer effective as of the same date. The filing describes Mr. Lally’s prior senior finance and operations roles at Ikena Oncology, Prevail Therapeutics and Arsanis, and notes he did not enter into any new material agreement, has no family relationships with directors or officers, and is not involved in related-party transactions requiring disclosure.

ImageneBio, Inc., formerly Ikena Oncology, completed its merger with Legacy Inmagene and now operates as a clinical-stage biopharmaceutical company focused on immune and inflammatory diseases. The business centers on IMG-007, a non-depleting anti-OX40 antibody initially developed for moderate-to-severe atopic dermatitis.

Early Phase 1b/2a data in atopic dermatitis showed meaningful and durable responses, including EASI‑75 rates of 54% and EASI‑90 rates of 31% at Week 16 after a four-week IV dosing period, with sustained biomarker improvements across Th1, Th2 and Th17 pathways. A multi-country Phase 2b subcutaneous dose-finding trial in atopic dermatitis is under way, with topline data expected in 2027.

The company sees IMG-007 as a potential “pipeline within a product,” with exploratory work in alopecia areata and possible future indications such as asthma, rheumatoid arthritis and hidradenitis suppurativa. However, the business remains entirely dependent on IMG-007’s success, expects significant ongoing losses, requires substantial additional funding, faces intense competition from established biologics and JAK inhibitors, and has disclosed a material weakness in internal controls over financial reporting.

ImageneBio, Inc. reported fourth quarter and full-year 2025 results and highlighted progress on its lead antibody IMG-007, now in the Phase 2b ADAPTIVE trial for moderate-to-severe atopic dermatitis.

For 2025, license revenue was $800 thousand compared with $3.5 million in 2024, reflecting lower collaboration income. Research and development expenses were $28.5 million and general and administrative expenses were $20.7 million, bringing total operating expenses to $49.3 million.

Net loss for 2025 was $45.3 million versus $36.6 million in 2024, as the company invested in building out operations after a reverse merger with Ikena Oncology and incurred transaction-related costs. Imagene ended 2025 with $135.3 million in cash, cash equivalents, and marketable securities, up from $12.1 million a year earlier, supported by the merger and a concurrent $75.0 million private placement.

ImageneBio, Inc. filed an initial insider ownership report for Benjamin Porter-Brown, who serves as Chief Medical Officer. This Form 3 does not list any share transactions or holdings, but formally registers his status as an officer subject to insider reporting rules.

ImageneBio, Inc. files a prospectus supplement registering 2,508,337 shares of common stock for resale by selling stockholders. The supplement incorporates parts of a Form 8-K dated February 17, 2026 and updates the Prospectus dated September 15, 2025.

The supplement states the last reported sales price was $6.85 per share on February 13, 2026. The Form 8-K disclosed that Steven Hui Wang resigned from the Board effective February 12, 2026, and the Company says his resignation was not due to any disagreement with the Company on operations, policies, practices or strategy.

ImageneBio, Inc. reported that Steven Hui Wang resigned from its Board of Directors, effective immediately on February 12, 2026. The company stated that his resignation was not due to any disagreement with ImageneBio regarding its operations, policies, practices, or strategy. The filing otherwise reflects routine corporate and listing information, including that ImageneBio’s common stock trades on the Nasdaq Capital Market under the symbol IMA.

Imagenebio, Inc. received an amended Schedule 13G showing that Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin now report zero beneficial ownership of the company’s common stock. Each reporting person lists 0 shares with 0% of the class and no voting or dispositive power. The filing confirms they own 5 percent or less of Imagenebio’s common stock. The ownership calculations use 11,181,672 shares outstanding as of November 3, 2025, as disclosed in Imagenebio’s prior quarterly report.

ImageneBio, Inc. received a Schedule 13G filing showing that Blue Owl Capital Holdings LP beneficially owns 823,785 shares of ImageneBio common stock. This represents 7.37% of the company’s outstanding common shares, based on 11,181,672 shares reported as outstanding as of November 3, 2025.

Blue Owl reports sole voting and dispositive power over all 823,785 shares and no shared power. The firm certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of ImageneBio.